#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	11794	16S	1529	1529	99.8	16S.l15.c4.ctg.1	2174	538.5	0	.	n	.	0	A69G	SNP	69	69	A	361	361	G	683	G,A	467,199	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	11794	16S	1529	1529	99.8	16S.l15.c4.ctg.1	2174	538.5	0	.	n	.	0	C450T	SNP	450	450	C	742	742	T	638	T,A	574,4	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	11794	16S	1529	1529	99.8	16S.l15.c4.ctg.1	2174	538.5	0	.	n	.	0	C1450T	SNP	1450	1450	C	1742	1742	T	626	T,C	572,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	11794	16S	1529	1529	99.8	16S.l15.c4.ctg.1	2174	538.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1476	1476	C	658	C,T	644,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	11794	16S	1529	1529	99.8	16S.l15.c4.ctg.1	2174	538.5	0	HET	.	.	.	C207T	.	207	207	C	499	499	C	660	C,T	490,138	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22312	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3509	631.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1679	1679	A	707	A	696	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22312	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3509	631.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2313	2313	C	634	C	620	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22312	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3509	631.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2387	2387	A	699	A	686	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22312	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3509	631.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	2939	2939	C	634	C,A	606,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_X_01360c	folP.WHO_X_01360c	1	1	539	1498	folP	852	852	99.88	folP.l15.c4.ctg.1	1380	107.4	0	.	p	.	0	E151K	NONSYN	451	453	GAA	706	708	AAA	149;144;143	A;A;A	144;140;137	.	.
folP.WHO_X_01360c	folP.WHO_X_01360c	1	1	539	1498	folP	852	852	99.88	folP.l15.c4.ctg.1	1380	107.4	1	SNP	p	R228S	1	.	.	682	684	AGC	937	939	AGC	133;133;133	A;G;C	131;131;130	folP.WHO_X_01360c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4338	gyrA	2751	2751	100.0	gyrA.l6.c30.ctg.1	3465	124.4	1	SNP	p	S91F	0	.	.	271	273	TCC	604	606	TCC	158;155;154	T,G;C;C	151,1;149;148	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4338	gyrA	2751	2751	100.0	gyrA.l6.c30.ctg.1	3465	124.4	1	SNP	p	D95N	0	.	.	283	285	GAC	616	618	GAC	151;146;148	G;A;C	145;136;145	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4338	gyrA	2751	2751	100.0	gyrA.l6.c30.ctg.1	3465	124.4	1	SNP	p	D95G	0	.	.	283	285	GAC	616	618	GAC	151;146;148	G;A;C	145;136;145	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	1352	mtrR	633	633	100.0	mtrR.l6.c30.ctg.1	1232	108.5	1	SNP	p	G45D	0	.	.	133	135	GGC	444	446	GGC	170;169;171	G;G,A;C	164;164,1;168	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	772	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1042	73.8	0	.	n	.	0	A197.	DEL	197	197	A	570	570	A	172	A	169	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3788	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3003	125.0	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1626	1628	GCA	146;144;146	G;C;A	143;127;125	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3788	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3003	125.0	1	SNP	p	D86N	0	.	.	256	258	GAC	579	581	GAC	156;155;157	G,C;A;C	152,1;144;154	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3788	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3003	125.0	1	SNP	p	S87W	0	.	.	259	261	AGT	582	584	AGT	156;158;159	A;G;T	147;155;148	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3788	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3003	125.0	1	SNP	p	S87I	0	.	.	259	261	AGT	582	584	AGT	156;158;159	A;G;T	147;155;148	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3788	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3003	125.0	1	SNP	p	S87R	0	.	.	259	261	AGT	582	584	AGT	156;158;159	A;G;T	147;155;148	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3788	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3003	125.0	1	SNP	p	S88P	0	.	.	262	264	TCC	585	587	TCC	159;159;162	T;C;C	154;154;159	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3214	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2606	122.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1535	1537	GGC	160;159;157	G;G;C,T	159;153;149,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.43.002	penA.43.002	1	1	539	3092	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2350	130.4	0	.	p	.	0	P552L	NONSYN	1654	1656	CCG	1944	1946	CTG	99;96;95	C,G;T;G	85,2;81;83	.	.
penA.43.002	penA.43.002	1	1	539	3092	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2350	130.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1221	1223	GCA	163;163;165	G,A;C;A	157,1;157;164	penA.43.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	3092	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2350	130.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1224	1226	ATC	165;165;165	A;T;C,T	162;162;161,1	penA.43.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	3092	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2350	130.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1236	1238	GTG	158;160;158	G;T;G	155;151;156	penA.43.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	3092	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2350	130.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1236	1238	GTG	158;160;158	G;T;G	155;151;156	penA.43.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	3092	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2350	130.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1740	1742	ACC	156;156;155	A;C;C	145;151;151	penA.43.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	3092	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2350	130.4	1	SNP	p	A502V	1	.	.	1504	1506	GTG	1794	1796	GTG	133;134;131	G,T;T,G;G,T	128,1;105,6;125,1	penA.43.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	3092	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2350	130.4	1	SNP	p	V502P	0	.	.	1504	1506	GTG	1794	1796	GTG	133;134;131	G,T;T,G;G,T	128,1;105,6;125,1	penA.43.002:1:1:V502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	3092	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2350	130.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1917	1919	GGC	122;117;116	G;G;C	121;115;114	penA.43.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	3092	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2350	130.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1926	1928	GGC	115;115;112	G;G;C	108;114;107	penA.43.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4736	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3187	147.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1688	1690	CCG	166;168;166	C;C;G,T	149;160;154,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1832	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1761	103.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	500	500	C	125	C	118	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	0	.	p	.	0	T89S	NONSYN	265	267	ACC	538	540	AGC	194;190;189	A;G;C	188;182;187	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	0	.	p	.	0	T106I	NONSYN	316	318	ACC	589	591	ATC	167;167;166	A;T;C,T	153;160;158,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	0	.	p	.	0	.	MULTIPLE	358	359	AA	630	631	CG	173;175	C;G,C	170;169,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	0	.	p	.	0	.	MULTIPLE	361	362	GA	633	635	CAG	176;177;181	C;A;G	171;170;176	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	0	.	p	.	0	N122K	NONSYN	364	366	AAC	637	639	AAA	184;182;184	A;A;A	178;179;182	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	664	666	TAT	192;188;186	T,C;A;T	186,1;186;183	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	0	.	p	.	0	N134E	NONSYN	400	402	AAT	673	675	GAG	185;183;183	G;A;G	180;177;183	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	0	.	p	.	0	V135F	NONSYN	403	405	GTG	676	678	TTT	183;183;180	T;T;T	168;182;178	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	0	.	p	.	0	G140K	NONSYN	418	420	GGA	691	693	AAA	186;185;182	A;A;A	182;182;179	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	0	.	p	.	0	K143E	NONSYN	427	429	AAA	700	702	GAA	184;184;186	G;A;A,C	178;175;176,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	0	.	p	.	0	V151A	NONSYN	451	453	GTA	724	726	GCA	185;185;184	G;C;A	180;179;171	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	0	.	p	.	0	R187Q	NONSYN	559	561	CGA	832	834	CAA	181;178;181	C;A;A	177;175;177	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	0	.	p	.	0	N189S	NONSYN	565	567	AAC	838	840	AGC	184;184;188	A;G;C	178;182;181	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	0	.	p	.	0	T213L	NONSYN	637	639	ACA	910	912	TTA	183;180;177	T;T;A	180;177;174	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	0	.	p	.	0	A244V	NONSYN	730	732	GCA	1003	1005	GTA	146;146;145	G;T;A	145;140;143	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1030	1032	CAA	144;142;142	C;A;A	143;142;139	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	0	.	p	.	0	.	INDELS	760	762	ACA	1034	1038	ATCAA	145;148;149;148;148	A;T;C;A;A	145;145;147;147;148	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	0	.	p	.	0	.	INDELS	763	764	TG	1041	1043	AGT	152;150;150	A;G;T	151;149;142	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1048	1050	GAT	156;156;153	G;A;T	153;153;150	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	0	.	p	.	0	V270A	NONSYN	808	810	GTA	1087	1089	GCG	166;164;167	G;C;G	156;158;161	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1156	1158	AGT	162;164;159	A;G;T	159;159;148	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	1	SNP	p	G120K	1	.	.	358	360	AAG	630	632	CGG	173;175;175	C;G,C;G	170;169,1;173	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	1	SNP	p	D121N	0	.	.	361	363	GAC	633	636	CGC	176;181;180	C;G;C	171;176;175	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2258	porB1b	1041	1041	96.09	porB1b.l15.c17.ctg.1	1593	141.0	1	SNP	p	A121D	1	.	.	361	363	GAC	633	636	CGC	176;181;180	C;G;C	171;176;175	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	8656	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5046	170.4	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2114	2116	CAT	206;205;207	C;A;T	200;200;201	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	988	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	981	99.6	1	SNP	p	V57M	1	.	.	169	171	ATG	456	458	ATG	181;181;179	A;T;G	177;176;177	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
